Metabolic reprogramming and epigenetic modifications on the path to cancer
作者机构:Guangzhou First People’s HospitalSchool of MedicineInstitutes for Life SciencesSouth China University of TechnologyGuangzhou 510006China The First Affiliated Hospital of USTCUniversity of Science and Technology of ChinaHefei 230027China CAS Centre for Excellence in Cell and Molecular Biologythe CAS Key Laboratory of Innate Immunity and Chronic DiseaseSchool of Basic Medical SciencesDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230027China School of Biomedical Sciences and EngineeringGuangzhou International CampusSouth China University of TechnologyGuangzhou 510006China Guangzhou Regenerative Medicine and Health Guangdong LaboratoryGuangzhou 510005China
出 版 物:《Protein & Cell》 (蛋白质与细胞(英文版))
年 卷 期:2022年第13卷第12期
页 面:877-919页
核心收录:
学科分类:0710[理学-生物学] 07[理学] 071007[理学-遗传学]
基 金:国家自然科学基金 National Key R&D Program of China 中国科学院项目 the Program for Guangdong Introducing Innovative and Entrepreneurial Teams Outstanding Scholar Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory 中央高校基本科研业务费专项资金
主 题:metabolic reprogramming epigenetics tumorigenesis tumor immunity cancer therapy
摘 要:Metabolic rewiring and epigenetic remodeling,which are closely linked and reciprocally regulate each other,are among the well-known cancer *** evi-dence suggests that many metabolites serve as sub-strates or cofactors of chromatin-modifying enzymes as a consequence of the translocation or spatial regional-ization of enzymes or *** metabolic alterations and epigenetic modifications also reportedly drive immune escape or impede immunosurveillance within certain contexts,playing important roles in tumor *** this review,we focus on how metabolic reprogramming of tumor cells and immune cells reshapes epigenetic alterations,in particular the acety-lation and methylation of histone proteins and *** also discuss other eminent metabolic modifications such as,succinylation,hydroxybutyrylation,and lacty-lation,and update the current advances in metabolism-and epigenetic modification-based therapeutic pro-spects in cancer.